Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in District of Columbia: - Medstar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish …
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05955261
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Network
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic…
Sponsor: Children's Oncology Group
NCT ID: NCT06247787
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, mole…
Sponsor: University of Oklahoma
NCT ID: NCT03633955
Sites in District of Columbia: - Children's National Health System — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Sponsor: Catherine Bollard
NCT ID: NCT02203903
Sites in District of Columbia: - Childrens National Medical Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06892158
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surv…
Sponsor: Cancer Support Community, Research and Training Institute, Philadelphia
NCT ID: NCT02333604
Sites in District of Columbia: - Cancer Support Community Research & Training Institute — Washington D.C., District of Columbia